Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline.
about
Unmet needs in the management of schizophreniaAn overview of diabetes management in schizophrenia patients: office based strategies for primary care practitioners and endocrinologistsQuality of medical care for persons with serious mental illness: A comprehensive reviewCardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT randomized controlled trial.A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients.Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care.Appraising evidence for intervention effectiveness in early psychosis: conceptual framework and review of evaluation approaches.Association of obesity and treated hypertension and diabetes with cognitive ability in bipolar disorder and schizophrenia.Quality of care for cardiometabolic disease: associations with mental disorder and rurality.Care provided by general practitioners to patients with psychotic disorders: a cohort studySex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum DisordersMonitoring and prevalence rates of metabolic syndrome in military veterans with serious mental illness.Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles.Inequalities in healthcare provision for people with severe mental illness.Community adherence to schizophrenia treatment and safety monitoring guidelines.Weight gain, obesity, and psychotropic prescribing.Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices.Past and present progress in the pharmacologic treatment of schizophrenia.Contextual Factors in the Health of People With Serious Mental Illness.Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level.Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetesThe serious mental illness health improvement profile [HIP]: study protocol for a cluster randomised controlled trial.Collaborative planning approach to inform the implementation of a healthcare manager intervention for Hispanics with serious mental illness: a study protocolA cardiometabolic psychiatry consultation service in a state psychiatric hospitalAccuracy of self-reported medical problems in patients with alcohol dependence and co-occurring schizophrenia or schizoaffective disorderMetabolic abnormalities among people diagnosed with schizophrenia: a literature review and implications for mental health nurses.Lower Incidence of End-Stage Renal Disease but Suboptimal Pre-Dialysis Renal Care in Schizophrenia: A 14-Year Nationwide Cohort Study.Sudden deaths in psychiatric patientsDoes a Physician's Attitude toward a Patient with Mental Illness Affect Clinical Management of Diabetes? Results from a Mixed-Method Study.Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs.Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensationThe Impact of Stakeholder Preferences on Service User Adherence to Treatments for Schizophrenia and Metabolic ComorbiditiesHigh Prevalence of Obesity, Hypertension, Hyperlipidemia, and Diabetes Mellitus in Japanese Outpatients with Schizophrenia: A Nationwide SurveyObese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness.Antipsychotic adherence and its correlation to health outcomes for chronic comorbid conditions.Explicit and Implicit Attitudes of Canadian Psychiatrists Toward People With Mental IllnessHigh prevalence of underweight and undernutrition in Japanese inpatients with schizophrenia: a nationwide survey.Metabolic syndrome in bipolar disordersMetabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective.
P2860
Q26822917-EE900DD9-D00E-4D2F-94BE-821A00516775Q26859927-B08BD3BB-7BBB-4148-B8D7-6FE00A5EF0C7Q27026165-D210395A-A039-4DFB-85F7-865FA454F27AQ30949176-0A436C78-0BC9-4458-AC79-FFC75438A93CQ33288884-D340FA72-CFE8-4BCE-8BA9-F33466F06B83Q33442059-83F4B665-6B56-4B6A-8380-10689513B990Q33533853-AD710A3F-25C8-49C4-AF89-B5679C6A2472Q33717601-23D11BDF-F461-42C0-92EA-CD57E60457FCQ33755431-6E9DDBE8-709E-4038-B768-5B45E8AD6DB0Q33756112-D6E3E526-7655-4302-B534-E7F65D7EDC7AQ33802927-A8321DEE-CF84-4C66-9480-2A983D92A574Q33889282-739FC426-06C8-4EEF-A58A-EE860A739C48Q34006864-734AA30E-61F1-42D7-BE1E-E5D6C064F062Q34183475-F54A34E8-FA85-4B3A-8E69-CE14E01D8017Q34496764-4CAF918F-C422-4392-9171-A601BB6A2765Q34557537-234EE478-7307-4E9C-9881-C4736EE20FD3Q34623350-853EE9F1-72D3-4704-9CC2-EB5FB1AADAA1Q34631699-9DDD2FBE-3C20-407A-A2F8-5C65E9881A64Q34726953-5A0DB128-855C-45F0-A24A-71FCEF0DEB95Q34774014-A552F9DF-6C92-4AE7-9C87-AB858AB81C20Q35016170-4E05D4CD-1329-49E9-9CF6-A0D63F98489EQ35049901-F4082016-FCB8-4D8E-80AA-8AAEFF5045CAQ35143800-8F2B240A-EFEE-4A17-925F-19068BF6517AQ35203803-582A4648-DDCE-4379-9854-7CB088B83700Q35252081-EC5371C3-A1BE-4351-89F0-5923E864E8EDQ35376156-687A2D50-2867-4A47-920E-CBC94D752B14Q35530406-763FAAC6-BC58-4E21-AED5-817DD5AAD60FQ35808831-E6AFBE06-0F8C-4B18-9572-F36F81388C41Q35834580-81CCF1F7-FA39-4BAC-9648-9800FBAFDDC0Q35984024-AF0A8D17-DD71-42F3-82B0-3512F5520744Q36063735-4FFFAA34-3E6D-4921-96FD-E0A49407DDD5Q36103530-62B28215-6F18-4612-8078-CD37B76FCFBDQ36193969-7EC2CECF-815F-4179-9312-7C023341C6E9Q36195246-CD981CB0-B760-4631-BC3D-1A4B9CAF7793Q36213557-F717589A-08C2-4197-8452-3FF31AEB26D6Q36302846-3539FC33-05CE-4B03-95D7-B849955C8167Q36371710-E4272F3C-E04D-45D8-9A4E-3FDAEA5D3F49Q36374026-A0A9D49B-01D1-492D-8E4F-B11BF7629CAAQ36400968-51157A6F-4445-4B6B-83B4-8A6490472B9FQ36474147-002A9B9D-D4B8-42BD-9281-2305475DCAE4
P2860
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Low rates of treatment for hyp ...... enia trial sample at baseline.
@ast
Low rates of treatment for hyp ...... enia trial sample at baseline.
@en
type
label
Low rates of treatment for hyp ...... enia trial sample at baseline.
@ast
Low rates of treatment for hyp ...... enia trial sample at baseline.
@en
prefLabel
Low rates of treatment for hyp ...... enia trial sample at baseline.
@ast
Low rates of treatment for hyp ...... enia trial sample at baseline.
@en
P2093
P1476
Low rates of treatment for hyp ...... enia trial sample at baseline.
@en
P2093
Henry A Nasrallah
Jeffrey A Lieberman
Jonathan M Meyer
Joseph P McEvoy
Sonia M Davis
T Scott Stroup
P356
10.1016/J.SCHRES.2006.06.026
P407
P577
2006-08-01T00:00:00Z